Why Is Clinical Trial Participation Vital for Diffuse Large B-Cell Lymphoma Patients?
Why Is Clinical Trial Participation Vital for Diffuse Large B-Cell Lymphoma Patients? from Patient Empowerment Network on Vimeo.
Why is it vital for diffuse large B-cell lymphoma (DLBCL) patients to participate in clinical trials? Expert Dr. Nirav Shah from the Medical College of Wisconsin shares his perspective on the benefits of clinical trial participation and advice for patients who are considering joining a trial.
Dr. Nirav Shah is an Associate Professor at the Medical College of Wisconsin. Learn more about Dr. Shah.
“…for clinical trials is, consider them. They may not be right for you, and that’s okay.”
See More from [ACT]IVATED DLBCL
Download Resource Guide en español
What Promising Treatments Are Available for Diffuse Large B-Cell Lymphoma Patients
How Can Patients Overcome Noted Diffuse Large B-Cell Lymphoma Disparities
Will Newer Therapies Be Curative for Diffuse Large B Cell Lymphoma Patients
Okay, Dr. Shah, why is clinical trial participation so important with DLBCL patients, and what advice do you have for those patients considering a clinical trial?
Dr. Nirav N. Shah:
Yeah, so number one, I always tell my patients one thing is it’s, clinical trials are an opportunity or an option, not a mandate. And so I never want a patient thinking that they have to participate in the clinical trial, participating in a clinical trial is an opportunity to help define potentially, the next treatment. Every treatment we’ve talked about up until this point was because kind, courageous people were willing to participate in a clinical trial. We wouldn’t have CAR T if hundreds of patients didn’t go on these clinical trials and be willing to be a subject and go through a treatment that was at the time undefined and without knowing how efficacious it was going to be.
And so clinical trials are important because without patients participating in clinical trials, how can we do better? That being said, a clinical trial is not right for every patient, and so it’s a value, it’s a judgment that each individual has to make. But I know that I really value my patients that are willing to participate because they all become part of that story about how to improve outcomes for diffuse large B-cell lymphoma for that patient who’s diagnosed five years from today or 10 years from today. And their participation, again, may not be recognized in the time that they’re participating, but what they did helps define the future of how we treat this disease. So my activation point for clinical trials is, consider them. They may not be right for you, and that’s okay.